Literature DB >> 18057668

[Secondary osteoporosis. Bisphosphonates as a possible strategy for the prevention of bone destruction in rheumatoid arthritis].

Yasuo Suzuki1.   

Abstract

Recent studies demonstrated that osteoclastic bone resorption played an important role in joint destruction by rheumatoid synovium. Bisphosphnates inhibit osteoclastic bone resorption and have been widely used for the treatment of osteoporosis. Bisphosphonates, such as zolendronic acid (ZA) inhibited bone destruction in animal models of inflammatory arthritis, although the drug was not effective for the suppression of inflammation. In early RA patients, ZA was effective to prevent bone destruction in combination with methotrexate. Targeting osteoclasts with bisphosphonates is an effective strategy to maintain joint integrity when combined with anti-rheumatic therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18057668     DOI: CliCa071219091913

Source DB:  PubMed          Journal:  Clin Calcium        ISSN: 0917-5857


  2 in total

1.  Severe polyarthritis secondary to zolendronic acid: a case report and literature review.

Authors:  Sarah Louise White; Alyssa Jacob; Celia Gregson; Ashok Bhalla
Journal:  Clin Cases Miner Bone Metab       Date:  2015 Jan-Apr

Review 2.  Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?

Authors:  Xiao-Long Xu; Wen-Long Gou; Ai-Yuan Wang; Yu Wang; Quan-Yi Guo; Qiang Lu; Shi-Bi Lu; Jiang Peng
Journal:  J Transl Med       Date:  2013-12-11       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.